The drug promotes lipophagy and hepatic fatty acid beta-oxidation to reduce liver fat, inflammation, and liver fibrosis.

The European Union's medicines regulator on Friday granted a conditional authorisation for Madrigal Pharmaceuticals' drug for ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease ...

Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved, ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

The liver fibrosis market is entering a transformative phase, driven by greater awareness, improved diagnostic ...

The bird flu outbreak affecting Brazil's poultry industry has led to international trade restrictions. The USDA is ...

Recent health highlights include Brazil battling avian flu export restrictions, the EU advancing a liver disease drug, ...